Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

Phase 3

Completed

• Conditions: Breast Cancer With Bone Metastasis
• Interventions: Drug: Zoledronic acid

• Registration Number: NCT00375427
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The objective of this study is to assess the clinical benefit of two different dosing schedules of zoledronic acid in patients with metastatic bone lesions from breast cancer who have already been treated with zoledronic acid for about one year.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02
• Study First Submitted: 2006-09-12
• Study First Submitted QC: 2006-09-12
• Study First Posted: 2006-09-13
• Primary Completion: 2010-02
• Results First Submitted: 2011-02-28
• Status Verified: 2011-07
• Results First Submitted QC: 2011-07-11
• Results First Posted: 2011-08-04
• Last Update Submitted: 2012-04-09
• Last Update Posted: 2012-04-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 430

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Every 3 months	Zoledronic acid	Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every three months. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Randomized patients will receive a maximum of 4 infusions in this group.
Every 4 weeks	Zoledronic acid	Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion every 4 weeks. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg. Patients randomized to this group will receive up to 12 infusions.

Primary Outcome Measures

Name	Time	Method
Annual Overall Skeletal Morbidity Rate (SMR)	12 months	The SMR was computed by summing all Skeletal Related Event(s) (SREs)which occurred during the observation period and dividing it by the ratio "days of observation period / 365.25", for each participant. SRE was defined as: pathologic bone fracture, spinal cord compression, surgery to bone both curative and prophylactic, radiation therapy to bone, or hypercalcemia of malignancy.; SMR (years) = 365.25 x SMR(days) where SMR (days) = total number of SREs / total SRE risk period (days). Risk period for SMR was computed as the days from randomization date to the date of last visit.

Secondary Outcome Measures

Name	Time	Method
Evaluation of Pain According to Verbal Rating Scale (VRS) Based on Median Score Value	At Baseline, Month 3, Month 6, Month 9 and Month 12	Pain intensity at rest and on movement is rated by the patient by means of a validated 6-point Verbal Rating Scale (VRS) and refers to the pain which occurred during the last week before the assessment. Median score value is the median of all the observed scores (none=0, very mild=1, mild=2, moderate=3, severe=5 and very severe=6) at each time point.
Percentage of Participants Experiencing Skeletal Related Event(s) (SREs)	12 month	Skeletal Related Events (SREs) are defined as a: * pathologic bone fracture such as non-vertebral and vertebral compression fractures; * spinal cord compression identified by positive diagnosis documented by X-ray evidence; * surgery to bone both curative and prophylactic; * radiation therapy to bone including palliative, therapeutic or prophylactic; * hypercalcemia of malignancy, defined as a corrected serum calcium \> 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration.
Median Time to First Skeletal Related Event(s) (SRE)	12 month	Median Time to first skeletal related event (SRE) is defined as the time from randomization to the date of first occurrence of any SRE which includes at least one of the following: radiation therapy to bone, pathologic bone fracture, spinal cord compression, surgery to bone, and hypercalcemia of malignancy (HCM). Due to the few numbers of SRE, Kaplan-Meier estimate never reaches a failure probability \>=25%; so median time, 25th and 75th percentiles are not determined.For this reason only the estimated percentage of patient SRE free are reported at each time point.
Annual Incidence of Any Skeletal Related Events (SREs)	12 months	Skeletal Related Events (SREs) are defined as a: * pathologic bone fracture such as non-vertebral and vertebral; * spinal cord compression identified by X-rays evidence; * surgery to bone both curative and prophylactic; * radiation therapy to bone including palliative, therapeutic or prophylactic; * hypercalcemia of malignancy, defined as a corrected serum calcium \> 12 mg/dl (3.00 mmol/l) or a lower level of hypercalcemia which is symptomatic and which requires active treatment other than rehydration. Annual incidence for each SRE was computed in the same way as annual overall SMR.
Percentage of Participants Skeletal Related Event (SRE) Free	12 months	Percentage of participants SRE free is defined as the Kaplan-Meier estimate of participants free of any Skeletal Related Events(SRE) at each time point.; Skeletal Related Events (SREs) are: * pathologic bone fracture; non-vertebral and vertebral; * spinal cord compression identified by X-rays; * surgery to bone both curative and prophylactic; * radiation therapy to bone (palliative, therapeutic or prophylactic); * hypercalcemia of malignancy, defined as a corrected serum calcium \> 12 mg/dl (3.00 mmol/l) or a lower level which is symptomatic and requires treatment other than rehydration.
Use Of Analgesic Medications According to the Analgesic Score Scale	At Baseline, Month 3, Month 6, Month 9 and Month 12	The analgesic score used for this study is modified from the Radiation Therapy Oncology Group (RTOG) analgesic score scale. The scale represents type of medication administered from 0 to 4 where: 0 = None; 1. = Minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.); 2. = Tranquilisers, antidepressants, muscle relaxants, and steroids; 3. = Mild narcotics (oxycodone, meperidine, codeine, etc.); 4. = Strong narcotics (morphine, hydromorphone, etc.) The outcome is given a the median score for the participants at Baseline and 3, 6, 9 and 12 months of treatment
Assessment of the Eastern Cooperative Oncology Group (ECOG) Performance Score	At Baseline, Month 3, Month 6, Month 9 and Month 12	ECOG Performance Score has 4 grades. 0 = Fully active, able to carry out all pre-disease activities; 1 = Restricted in strenuous activity but ambulatory and able to carry out work of light or sedentary nature; 2 = Ambulatory and capable of all self-care but unable to carry out work activities. Active about 50% of waking hours; 3 = Capable of limited self-care, confined to bed/chair more than 50% of waking hours; 4 = Completely disabled; cannot carry on self-care. Totally confined to bed/chair. Outcome is given as median score for participants at Baseline and 3, 6 , 9 and 12 months of treatment
Composite Bone Pain Score According to the Brief Pain Inventory (BPI) Questionnaire	At Baseline, Month 3, Month 6, Month 9 and Month 12	Bone pain was assessed by means of a pain score obtained using the Brief Pain Inventory (BPI) questionnaire. The BPI can produce three pain scores: worst pain, a composite pain score, and a pain interference score. The composite pain score, which is the average of questions 3, 4, 5 and 6 of the questionnaire was used in this study. Pain was rated on a scale of 0 (no pain) to 10 (pain as bad as you can imagine). The outcome is given as the median score for participants at baseline, and 3, 6, 9 and 12 months of treatment

Trial Locations

Locations (1)

Novartis Investigative Site; 🇮🇹 Forlì, Italy